AXIM Biotechnologies, Inc. (AXIM)
USD 0.0
(17.65%)
USD 0.0
(17.65%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 5.42 Million USD | -3.87% |
| 2022 | 5.64 Million USD | 11.11% |
| 2021 | 5.08 Million USD | -14.07% |
| 2020 | 5.91 Million USD | 16.92% |
| 2019 | 5.05 Million USD | 4.33% |
| 2018 | 4.84 Million USD | 528.26% |
| 2017 | 771.52 Thousand USD | -4.03% |
| 2016 | 803.93 Thousand USD | 100.98% |
| 2015 | 400 Thousand USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 6.22 Million USD | 0.98% |
| 2024 Q1 | 6.16 Million USD | 13.54% |
| 2023 FY | 5.42 Million USD | -3.87% |
| 2023 Q2 | 5.63 Million USD | 5.44% |
| 2023 Q4 | 5.42 Million USD | -5.15% |
| 2023 Q3 | 5.72 Million USD | 1.59% |
| 2023 Q1 | 5.34 Million USD | -5.38% |
| 2022 Q3 | 5.57 Million USD | 0.62% |
| 2022 FY | 5.64 Million USD | 11.11% |
| 2022 Q4 | 5.64 Million USD | 1.22% |
| 2022 Q1 | 5.12 Million USD | 0.91% |
| 2022 Q2 | 5.54 Million USD | 8.11% |
| 2021 Q3 | 5.66 Million USD | 0.97% |
| 2021 Q4 | 5.08 Million USD | -10.32% |
| 2021 Q1 | 5.98 Million USD | 1.25% |
| 2021 Q2 | 5.61 Million USD | -6.27% |
| 2021 FY | 5.08 Million USD | -14.07% |
| 2020 FY | 5.91 Million USD | 16.92% |
| 2020 Q1 | 5.05 Million USD | -0.12% |
| 2020 Q2 | 5.27 Million USD | 4.53% |
| 2020 Q3 | 5.9 Million USD | 11.78% |
| 2020 Q4 | 5.91 Million USD | 0.18% |
| 2019 Q4 | 5.05 Million USD | 1.36% |
| 2019 FY | 5.05 Million USD | 4.33% |
| 2019 Q2 | 4.92 Million USD | 0.15% |
| 2019 Q1 | 4.91 Million USD | 1.38% |
| 2019 Q3 | 4.98 Million USD | 1.37% |
| 2018 Q3 | 801.22 Thousand USD | 4.87% |
| 2018 FY | 4.84 Million USD | 528.26% |
| 2018 Q4 | 4.84 Million USD | 504.97% |
| 2018 Q2 | 764.01 Thousand USD | 4.3% |
| 2018 Q1 | 732.54 Thousand USD | -5.05% |
| 2017 FY | 771.52 Thousand USD | -4.03% |
| 2017 Q2 | 2.9 Million USD | 243.12% |
| 2017 Q3 | 1.44 Million USD | -50.22% |
| 2017 Q4 | 771.52 Thousand USD | -46.72% |
| 2017 Q1 | 847.69 Thousand USD | 5.44% |
| 2016 Q4 | 803.93 Thousand USD | 153.39% |
| 2016 Q2 | 310.49 Thousand USD | -22.38% |
| 2016 Q1 | 400 Thousand USD | 0.0% |
| 2016 FY | 803.93 Thousand USD | 100.98% |
| 2016 Q3 | 317.26 Thousand USD | 2.18% |
| 2015 Q3 | 400 Thousand USD | 0.0% |
| 2015 Q4 | 400 Thousand USD | 0.0% |
| 2015 Q2 | 400 Thousand USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 FY | 400 Thousand USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | - USD | -Infinity% |
| Evofem Biosciences, Inc. | 8000.00 USD | -67731.0% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 1.75 Million USD | -209.117% |
| Qrons Inc. | 80 Thousand USD | -6683.1% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 20.31 Million USD | 73.284% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Skye Bioscience, Inc. | 171.23 Thousand USD | -3069.118% |
| Eiger BioPharmaceuticals, Inc. | - USD | -Infinity% |
| Nanobac Pharmaceuticals, Incorporated | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 20.9 Million USD | 74.047% |
| Intellipharmaceutics International Inc. | - USD | -Infinity% |
| Propanc Biopharma, Inc. | 58.64 Thousand USD | -9153.573% |
| Mesoblast Limited | 100.29 Million USD | 94.589% |
| Marizyme, Inc. | 667.12 Thousand USD | -713.408% |
| Genus plc | 228.2 Million USD | 97.622% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 166.1 Million USD | 96.733% |
| Therapeutic Solutions International, Inc. | 5512.00 USD | -98348.476% |
| CNBX Pharmaceuticals Inc. | - USD | -Infinity% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| ContraFect Corporation | 2.21 Million USD | -145.542% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.4 Million USD | -286.795% |
| IMV Inc. | 27.39 Million USD | 80.194% |
| MultiCell Technologies, Inc. | 36.43 USD | -14895535.465% |
| ONE Bio Corp. | 592.19 Thousand USD | -816.329% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 55.61 Million USD | 90.242% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | - USD | -Infinity% |
| Q BioMed Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 2.22 Million USD | -143.777% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -341.766% |
| Biomind Labs Inc. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 554.59 Thousand USD | -878.467% |
| Provectus Biopharmaceuticals, Inc. | 25.29 Thousand USD | -21349.385% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 1.89 Million USD | -185.835% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| GB Sciences, Inc. | 322 Thousand USD | -1585.242% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 11.23 Billion USD | 99.952% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | 150 Thousand USD | -3517.653% |
| Enzolytics Inc. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 164.2 Thousand USD | -3204.698% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 15.35 Million USD | 64.658% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 4456.00 USD | -121679.174% |
| Genscript Biotech Corporation | 287.12 Million USD | 98.11% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 126.3 Thousand USD | -4196.432% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -2266.635% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| Kadimastem Ltd | 229.69 Thousand USD | -2262.513% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 8.26 Million USD | 34.336% |
| BioStem Technologies, Inc. | 265.63 Thousand USD | -1942.833% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 1064.00 USD | -509907.519% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -3526.987% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -3526.987% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | - USD | -Infinity% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | 141 Thousand USD | -3748.567% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 30.607% |
| SYBLEU INC | 300 Thousand USD | -1708.827% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 369.04 Thousand USD | -1370.396% |
| International Stem Cell Corporation | 445 Thousand USD | -1119.434% |
| Bioxytran, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.15 Million USD | 33.417% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | 457 Thousand USD | -1087.414% |
| Neutra Corp. | - USD | -Infinity% |
| Windtree Therapeutics, Inc. | 1.16 Million USD | -367.397% |
| PureTech Health plc | 18.25 Million USD | 70.266% |
| Coeptis Therapeutics, Inc. | 150 Thousand USD | -3517.653% |
| IXICO plc | 275 Thousand USD | -1873.265% |
| IntelGenx Technologies Corp. | 11.83 Million USD | 54.164% |
| Gelesis Holdings, Inc. | 26.3 Million USD | 79.374% |
| CSL Limited | 11.23 Billion USD | 99.952% |
| Cellectis S.A. | 36.21 Million USD | 85.014% |